Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
Ashraf Mahmoud El-Enbaby, Nadia Ahmed Abd El Moneim, Gehan Abd El atti Khedr, Yasmine Mohamed Nagy Elwany
Korean J Clin Oncol. 2018;14(2):108-115.   Published online 2018 Dec 31     DOI: https://doi.org/10.14216/kjco.18019
Citations to this article as recorded by Crossref logo
A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer
Wala Ben Kridis, Syrine Sghaier, Salma Charfeddine, Nabil Toumi, Jamel Daoud, Samir Kammoun, Afef Khanfir
American Journal of Clinical Oncology.2020; 43(7): 510.     CrossRef